Article
Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma.
Cancer research - 1 Dec 2023
Ferretti Lorenza P, Böhi Flurina, Leslie Pedrioli Deena M, Cheng Phil F, Ferrari Elena, Baumgaertner Petra, Alvarado-Diaz Abdiel, Sella Federica, Cereghetti Alessandra, Turko Patrick, Wright Roni H, De Bock Katrien, Speiser Daniel E, Ferrari Roberto, Levesque Mitchell P, Hottiger Michael O
Abstract excerpt
Metastatic melanoma is either intrinsically resistant or rapidly acquires resistance to targeted therapy treatments, such as MAPK inhibitors (MAPKi). A leading cause of resistance to targeted therapy is a dynamic transition of melanoma cells from a proliferative to a highly invasive state, a phenomenon called phenotype switching. Mechanisms regulating phenotype switching represent potential targets for improving...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.